An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables

Contraception

Volumn 65, Issue 3, 2002, Pages 215-221

  Endrikat, J ^a   Klipping, C ^b   Cronin, M ^a   Gerlinger, C ^a   Ruebig, A ^a   Schmidt, W ^c   Dusterberg B ^a  

^a BAYER PHARMA AG   (Germany)

^b Dinox Medical Investigations   (Netherlands)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

Carbohydrate metabolism; Dose reduction; Ethinyl estradiol; Hemostasis; Levonorgestrel; Lipids; Oral contraceptives

Indexed keywords

CARBOHYDRATE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL CONTRACEPTIVE AGENT; PROTHROMBIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CARBOHYDRATE METABOLISM; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HEMOSTASIS; HUMAN; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; NORMAL HUMAN; ORAL CONTRACEPTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; CARBOHYDRATES; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, SYNTHETIC; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHINYL ESTRADIOL; FEMALE; HEMOSTASIS; HUMANS; LEVONORGESTREL; LIPIDS; NETHERLANDS; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 0036210707     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(01)00316-X     Document Type: Article

References (22)

1. A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene
2. German trial of an oral contraceptive containing 0.150 mg desogestrel plus 0.020 mg ethinylestadiol
3. A review of 'once-a-month' combined injectable contraceptives
4. A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel over six treatment cycles
5. Large observational trial of a new low-dose oral contraceptive containing 20 μg ethinylestradiol and 100 μg levonorgestrel (Miranova) in Germany
6. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study
7. A comparative study of the effects on the hemostatic system of two monophasic gestodene oral contraceptives containing 20 μg and 30 μg ethinylestradiol
8. Safety evaluation of mordern oral contraceptives
9. Importance of levonorgestrel dose in oral contraceptives for effects on coagulation
10. Consensus development meeting.: Combined oral contraceptives, and cardiovascular disease. The consensus statement issued after the Second European Conference on Sex Steroids and Metabolism
11. Ethinylestradiol 20 versus 30 μg combined with 150 μg desogestrel: A large comparative study of the effects of two low-dose oral contraceptives on the hemostatic system
12. A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 μg ethinylestradiol and either 2 mg chlormadinone acetate or 150 μg desogestrel
13. Blood coagulation and oral contraceptives
14. An open label, randomized study to evaluate the effects of seven monophasic oral contraceptive regimens on hemostatic variables
15. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down-regulation of fibrinolysis
16. Effects on hemostasis after two-year use of low dose combined oral contraceptives with gestodene or levonorgestrel
17. Effects on coagulation of levorgestrel- and desogestrel-containing low dose oral contraceptives: A cross-over study
18. Influence of two low-dose oral contraceptives containing ethinylestradiol (20 μg) and desogestrel or gestodene on carbohydrate metabolism during 1 year of use
19. Low-dose combined oral contraceptives
20. Defects in carbohydrate metabolism in oral contraceptive users without apparent metabolic risk factors
21. Insulin resistance, secretion, and metabolism in users of oral contraceptives